APRI - Apricus Biosciences Stock Price, News & Analysis

$1.59 0.00 (0.00 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$1.59
Today's Range$1.58 - $1.63
52-Week Range$0.86 - $4.07
Volume75,876 shs
Average Volume659,237 shs
Market Capitalization$24.65 million
P/E RatioN/A
Dividend YieldN/A
Beta0.5

About Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences logoApricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:APRI
  • CUSIP: N/A
  • Web: www.apricusbio.com
Debt:
  • Current Ratio: 4.80%
  • Quick Ratio: 4.80%
Sales & Book Value:
  • Annual Sales: $5.76 million
  • Price / Sales: 4.20
  • Book Value: $0.41 per share
  • Price / Book: 3.88
Profitability:
  • Trailing EPS: $0.58
  • Net Income: $-7,430,000.00
  • Return on Equity: -527.09%
  • Return on Assets: -126.76%
Misc:
  • Employees: 15
  • Outstanding Shares: 15,220,000
 

Frequently Asked Questions for Apricus Biosciences (NASDAQ:APRI)

What is Apricus Biosciences' stock symbol?

Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."

How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences, Inc (NASDAQ:APRI) issued its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.30) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.15. During the same period in the prior year, the business earned ($0.19) EPS. View Apricus Biosciences' Earnings History.

Where is Apricus Biosciences' stock going? Where will Apricus Biosciences' stock price be in 2017?

2 equities research analysts have issued 1 year target prices for Apricus Biosciences' stock. Their forecasts range from $4.50 to $4.50. On average, they expect Apricus Biosciences' share price to reach $4.50 in the next year. View Analyst Ratings for Apricus Biosciences.

Who are some of Apricus Biosciences' key competitors?

Who are Apricus Biosciences' key executives?

Apricus Biosciences' management team includes the folowing people:

  • Kleanthis G. Xanthopoulos Ph.D., Chairman of the Board (Age 57)
  • Richard W. Pascoe, Chief Executive Officer, Principal Accounting Officer, Secretary, Director (Age 52)
  • Brian T. Dorsey, Senior Vice President, Chief Development Officer (Age 47)
  • Paul V. Maier, Independent Director (Age 69)
  • Rusty Ray, Independent Director (Age 45)
  • Sandford D. Smith, Independent Director (Age 70)
  • Wendell Wierenga Ph.D., Independent Director (Age 69)

How do I buy Apricus Biosciences stock?

Shares of Apricus Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apricus Biosciences' stock price today?

One share of Apricus Biosciences stock can currently be purchased for approximately $1.59.

How big of a company is Apricus Biosciences?

Apricus Biosciences has a market capitalization of $24.65 million and generates $5.76 million in revenue each year. The company earns $-7,430,000.00 in net income (profit) each year or $0.58 on an earnings per share basis. Apricus Biosciences employs 15 workers across the globe.

How can I contact Apricus Biosciences?

Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]


MarketBeat Community Rating for Apricus Biosciences (APRI)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Apricus Biosciences (NASDAQ:APRI)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.50 (183.02% upside)

Consensus Price Target History for Apricus Biosciences (NASDAQ:APRI)

Price Target History for Apricus Biosciences (NASDAQ:APRI)

Analysts' Ratings History for Apricus Biosciences (NASDAQ:APRI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017HC WainwrightReiterated RatingBuy$4.50N/AView Rating Details
4/26/2017Rodman & RenshawInitiated CoverageBuy -> BuyLowView Rating Details
3/15/2016Taglich BrothersLower Price TargetSpeculative Buy$4.25 -> $2.95N/AView Rating Details
3/11/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
12/9/2015Sterne Agee CRTDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Apricus Biosciences (NASDAQ:APRI)

Earnings by Quarter for Apricus Biosciences (NASDAQ:APRI)

Earnings History by Quarter for Apricus Biosciences (NASDAQ APRI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.15)($0.30)ViewN/AView Earnings Details
8/2/2017Q2 2017($0.16)($0.15)ViewListenView Earnings Details
5/11/2017Q1 2017$1.25$1.04$12.00 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.15)($0.04)$3.44 million$0.40 millionViewN/AView Earnings Details
11/8/2016Q316($0.60)($0.19)$1.91 million$4.30 millionViewListenView Earnings Details
8/4/2016Q216($0.08)($0.05)$1.78 million$0.46 millionViewListenView Earnings Details
5/9/2016Q116($0.09)($0.09)$0.83 million$0.63 millionViewN/AView Earnings Details
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details
8/5/2015Q2($0.13)($0.10)$0.70 million$0.46 millionViewListenView Earnings Details
5/11/2015Q1($0.10)($0.13)$0.95 million$0.48 millionViewListenView Earnings Details
3/16/2015Q4($0.12)($0.09)$0.67 million$1.91 millionViewListenView Earnings Details
11/10/2014Q314($0.09)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details
3/17/2014Q212($0.06)($0.04)$2.00 million$0.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Apricus Biosciences (NASDAQ:APRI)
2017 EPS Consensus Estimate: ($0.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Apricus Biosciences (NASDAQ:APRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Apricus Biosciences (NASDAQ APRI)

Insider Ownership Percentage: 3.55%
Institutional Ownership Percentage: 12.94%
Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)
Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)

Insider Trades by Quarter for Apricus Biosciences (NASDAQ APRI)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017Alexander J DennerMajor ShareholderBuy6,104$1.63$9,949.52View SEC Filing  
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Apricus Biosciences (NASDAQ APRI)

Source:
DateHeadline
Should You Buy Apricus Biosciences Inc (APRI) Now?Should You Buy Apricus Biosciences Inc (APRI) Now?
finance.yahoo.com - November 21 at 4:33 PM
Zacks: Analysts Expect Apricus Biosciences, Inc (APRI) to Post -$0.13 Earnings Per ShareZacks: Analysts Expect Apricus Biosciences, Inc (APRI) to Post -$0.13 Earnings Per Share
www.americanbankingnews.com - November 14 at 1:24 PM
Equities Analysts Set Expectations for Apricus Biosciences, Incs FY2017 Earnings (APRI)Equities Analysts Set Expectations for Apricus Biosciences, Inc's FY2017 Earnings (APRI)
www.americanbankingnews.com - November 10 at 8:34 AM
Zacks Investment Research Lowers Apricus Biosciences, Inc (APRI) to SellZacks Investment Research Lowers Apricus Biosciences, Inc (APRI) to Sell
www.americanbankingnews.com - November 7 at 9:46 PM
SeeThruEquity Issues Update Note on Apricus Biosciences, Inc. (Nasdaq CM: APRI) with Target Price of $4.30SeeThruEquity Issues Update Note on Apricus Biosciences, Inc. (Nasdaq CM: APRI) with Target Price of $4.30
finance.yahoo.com - November 7 at 5:42 PM
HC Wainwright Reiterates "Buy" Rating for Apricus Biosciences, Inc (APRI)HC Wainwright Reiterates "Buy" Rating for Apricus Biosciences, Inc (APRI)
www.americanbankingnews.com - November 4 at 11:32 PM
Analyzing Apricus Biosciences (APRI) and Corium International (CORI)Analyzing Apricus Biosciences (APRI) and Corium International (CORI)
www.americanbankingnews.com - November 3 at 9:14 PM
Apricus Biosciences, Inc (APRI) Posts  Earnings ResultsApricus Biosciences, Inc (APRI) Posts Earnings Results
www.americanbankingnews.com - November 3 at 8:46 PM
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 3 at 9:22 AM
Edited Transcript of APRI earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of APRI earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 3 at 9:22 AM
EARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q3 Earnings Report
www.rttnews.com - November 2 at 9:33 PM
Apricus reports 3Q lossApricus reports 3Q loss
finance.yahoo.com - November 2 at 9:33 PM
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results - NasdaqApricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - November 2 at 4:28 PM
Apricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial ResultsApricus Biosciences Provides Corporate Update and Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 4:28 PM
Apricus Biosciences, Inc (APRI) Lifted to Buy at Zacks Investment ResearchApricus Biosciences, Inc (APRI) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - October 31 at 8:36 PM
Apricus Biosciences, Inc (APRI) Scheduled to Post Earnings on MondayApricus Biosciences, Inc (APRI) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 3:28 AM
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call - GlobeNewswire (press release)Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call - GlobeNewswire (press release)
globenewswire.com - October 26 at 3:59 PM
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call - NasdaqApricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call - Nasdaq
www.nasdaq.com - October 26 at 10:25 AM
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference CallApricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call
finance.yahoo.com - October 26 at 10:25 AM
Analyzing Apricus Biosciences (APRI) & The CompetitionAnalyzing Apricus Biosciences (APRI) & The Competition
www.americanbankingnews.com - October 22 at 10:18 PM
Apricus Biosciences (APRI) Presents At 2017 BIO Investor Forum - SlideshowApricus Biosciences (APRI) Presents At 2017 BIO Investor Forum - Slideshow
seekingalpha.com - October 18 at 5:14 PM
Apricus Biosciences to Present at the 2017 BIO Investor Forum - NasdaqApricus Biosciences to Present at the 2017 BIO Investor Forum - Nasdaq
www.nasdaq.com - October 11 at 5:30 PM
Should You Be Concerned About Apricus Biosciences Inc’s (APRI) Risks?Should You Be Concerned About Apricus Biosciences Inc’s (APRI) Risks?
finance.yahoo.com - October 10 at 10:19 PM
Apricus Biosciences to Present at the 2017 BIO Investor ForumApricus Biosciences to Present at the 2017 BIO Investor Forum
finance.yahoo.com - October 10 at 5:18 PM
 Analysts Expect Apricus Biosciences, Inc (APRI) to Announce -$0.15 EPS Analysts Expect Apricus Biosciences, Inc (APRI) to Announce -$0.15 EPS
www.americanbankingnews.com - October 6 at 4:28 AM
SeeThruEquity Issues Company Update on Apricus Biosciences (NASDAQ:APRI) with Target Price of $4.30SeeThruEquity Issues Company Update on Apricus Biosciences (NASDAQ:APRI) with Target Price of $4.30
finance.yahoo.com - October 3 at 3:43 PM
Head to Head Review: Apricus Biosciences (APRI) vs. Its CompetitorsHead to Head Review: Apricus Biosciences (APRI) vs. Its Competitors
www.americanbankingnews.com - September 28 at 6:22 AM
Critical Survey: Aralez Pharmaceuticals (ARLZ) and Apricus Biosciences (APRI)Critical Survey: Aralez Pharmaceuticals (ARLZ) and Apricus Biosciences (APRI)
www.americanbankingnews.com - September 27 at 4:32 PM
BRIEF-Apricus Biosciences says Armistice Capital reports a 9.6 pct passive stake in coBRIEF-Apricus Biosciences says Armistice Capital reports a 9.6 pct passive stake in co
www.reuters.com - September 20 at 9:45 PM
BRIEF-Apricus Biosciences announces $3.7 million private placement priced at-the-marketBRIEF-Apricus Biosciences announces $3.7 million private placement priced at-the-market
www.reuters.com - September 12 at 4:13 PM
Apricus Biosciences (APRI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowApricus Biosciences (APRI) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 12 at 4:13 PM
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market - GlobeNewswire (press release)Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market - GlobeNewswire (press release)
globenewswire.com - September 11 at 3:48 PM
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-MarketApricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
finance.yahoo.com - September 11 at 3:48 PM
Head to Head Survey: Apricus Biosciences (APRI) and Eyegate Pharmaceuticals (EYEG)Head to Head Survey: Apricus Biosciences (APRI) and Eyegate Pharmaceuticals (EYEG)
www.americanbankingnews.com - September 7 at 12:50 PM
Apricus, Topical Formulations Leading the Way, Q2 Review, and OutlookApricus, Topical Formulations Leading the Way, Q2 Review, and Outlook
finance.yahoo.com - September 6 at 3:56 PM
Apricus Biosciences, Inc.: Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceApricus Biosciences, Inc.: Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
www.finanznachrichten.de - September 5 at 5:37 PM
Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment ConferenceApricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 5 at 5:37 PM
PDUFA Run-Up Idea: Apricus Biosciences - Seeking AlphaPDUFA Run-Up Idea: Apricus Biosciences - Seeking Alpha
seekingalpha.com - September 4 at 4:28 PM
Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission - GlobeNewswire (press release)Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission - GlobeNewswire (press release)
globenewswire.com - August 31 at 3:52 PM
Apricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA ResubmissionApricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission
finance.yahoo.com - August 31 at 3:52 PM
Apricus resubmits US marketing application for ED cream Vitaros - Seeking AlphaApricus resubmits US marketing application for ED cream Vitaros - Seeking Alpha
seekingalpha.com - August 31 at 3:13 AM
Apricus Biosciences, Inc (APRI) Given a $5.00 Price Target at HC WainwrightApricus Biosciences, Inc (APRI) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - August 30 at 11:16 AM
Apricus Biosciences, Inc.: Apricus Biosciences Files NDA Resubmission for Vitaros™Apricus Biosciences, Inc.: Apricus Biosciences Files NDA Resubmission for Vitaros™
www.finanznachrichten.de - August 30 at 2:17 AM
BRIEF-Apricus Biosciences files NDA resubmission for VitarosBRIEF-Apricus Biosciences files NDA resubmission for Vitaros
www.reuters.com - August 30 at 2:17 AM
Apricus Biosciences, Inc (APRI) Expected to Announce Earnings of -$0.15 Per ShareApricus Biosciences, Inc (APRI) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - August 29 at 10:26 PM
Apricus Biosciences Files NDA Resubmission for Vitaros™ - GlobeNewswire (press release)Apricus Biosciences Files NDA Resubmission for Vitaros™ - GlobeNewswire (press release)
globenewswire.com - August 29 at 4:16 PM
Apricus Biosciences Files NDA Resubmission for Vitaros™Apricus Biosciences Files NDA Resubmission for Vitaros™
finance.yahoo.com - August 29 at 4:16 PM
ETFs with exposure to Apricus Biosciences, Inc. : August 11, 2017ETFs with exposure to Apricus Biosciences, Inc. : August 11, 2017
finance.yahoo.com - August 11 at 9:29 PM
 Brokerages Anticipate Apricus Biosciences, Inc (NASDAQ:APRI) to Post -$0.15 Earnings Per Share Brokerages Anticipate Apricus Biosciences, Inc (NASDAQ:APRI) to Post -$0.15 Earnings Per Share
www.americanbankingnews.com - August 11 at 4:44 PM
Drug Makers Stock Performance Review -- DURECT, Sucampo Pharma, Apricus Biosciences, and MEI Pharma - PR Newswire (press release)Drug Makers Stock Performance Review -- DURECT, Sucampo Pharma, Apricus Biosciences, and MEI Pharma - PR Newswire (press release)
www.prnewswire.com - August 8 at 8:49 PM

Social Media

Financials

Chart

Apricus Biosciences (NASDAQ APRI) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.